Skip to content
ppharmaranks
Menu
Class IIOngoing

Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL recall

FDA recall D-0251-2026 · initiated Dec 18, 2025

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Jan 14, 2026How we research

Imprimis NJOF, LLC recalled Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL in Dec 2025 — an FDA Class II recall (D-0251-2026) because Presence of particulate matter - Glass like particles.

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Presence of particulate matter - Glass like particles.

Something got into the product

A physical or chemical contaminant was found — glass or metal fragments, or a solvent that should not be there.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot: 25JAN033A, 25JAN033B, Expires: 02/12/2026.

Quantity recalled: 314 boxes of 6,280 pre-filled syringes

Details

Product
Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06.
Recalling company
Imprimis NJOF, LLC
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
U.S Nationwide
Initiated
Dec 18, 2025
FDA report date
Jan 14, 2026
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL recalled?
Imprimis NJOF, LLC recalled Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL in Dec 2025 — an FDA Class II recall (D-0251-2026) because Presence of particulate matter - Glass like particles. May cause temporary or medically reversible harm; low probability of serious harm.
Why was Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL recalled?
Per the FDA enforcement record, the reason for recall D-0251-2026 was: Presence of particulate matter - Glass like particles.
Is a recalled Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL are affected?
Distributed: U.S Nationwide. The recall covers these lots — Lot: 25JAN033A, 25JAN033B, Expires: 02/12/2026.. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0251-2026.

Source: openFDA Drug Enforcement record D-0251-2026

← All drug recalls